文献リスト

1) Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007; April 9 (Epub, ahead of print)

2) Samson D. Principles of chemotherapy and radiotherapy. In: Gahrton G, Durie BGM, editors. Multiple myeloma. London: Arnold; 1996. p. 108-29

3) Myeloma Trialists' Collaborative Group. Combination chemotherapy vs melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol. 1998; 16: 3832-42

4) Attal M, Harousseau JL, Stoppa AM, et al. Intergroupe Francais du Myelome. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996; 335: 91-7

5) Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-83

6) Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004; 104: 3052-7

7) The UK Myeloma Forum Guidelines Working Group. Guideline. Diagnosis and management of multiple myeloma. Br J Haematol. 2001; 115: 522-40

8) Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4: 379-98

9) Hahn T, Wingard JR, Anderson KC, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003; 9: 4-37

10) Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349: 2495-502

11) Barlogie B, Anaissie E, Bolejack V, et al. High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants: early results of total therapy 3. J Clin Oncol. 2006; 18(suppl): 426s. Abstract# 7519

12) Barbui AM, Galli M, Dotti G, et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol. 2002; 116: 202-10

13) Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. J Clin Oncol. 2006; 24: 929-36

14) Harousseau JL, Moreau P. Role of bone marrow transplantation in the disease pathway of myeloma. J Natl Compr Canc Netw. 2007; 5: 281-90

15) Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007; 109: 3588-94

16) Garban F, Attal M, Michalett M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006; 107: 3474-80

17) Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007; 356: 1110-20

18) Kumar SK, Terry M, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004; 79: 867-74

19) 清水 一之. 特集1・造血器腫瘍の分子標的療法の進歩-がん治療のパラダイム- 7. 多発性骨髄腫. 血液フロンテイア. 2006; 16: 95-117

20) Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Bood. 2007; 109: 3489-95

21) Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trial, patient counseling and choice of therapy. Leukemia. 2007; 21: 529-34

22) Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus statement. Mayo Clin Proc. 2007; 82: 323-41

23) Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2007; 48: 46-55

24) Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med. 2004; 117: 508-15

25) Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006; 24: 431-6

26) Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy for autologous transplantation for multiple myeloma. Blood. 2005; 106: 35-9

27) Anderson KC, Richardson PG. Correspondence. J Clin Oncol. 2006; 24: 2968-9

28) Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006; 367: 825-31

29) Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan-prednisone (MP) ＋ thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood. 2005; 106: abstract #780

30) Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108: 3289-94

31) Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001; 97: 1566-71

32) Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-30

33) Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006; 108: 1724-32

34) Chang H, Trieu Y, Qi Xiaoying, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2006; Sept 20 (Epub ahead of print)

35) Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007; 21: 151-7

36) Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007; 21: 164-8

37) Richardson PG, Barlogie B, Berenson B, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005; 106: 2977-81

38) Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for peviously untreated symptomatic multiple myeloma. Br J Haematol. 2005; 129: 776-83

39) Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91: 1498-505

40) Oakervee HE, Popa R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin, dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005; 129: 755-62

41) Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood. 2005; 106: 231a. Abstract# 784

42) Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006; 108: 2165-72

43) Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106: 4050-3

44) Lacy M, Gertz M, Dispenzieri A, et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood. 2006; 108: 239a. Abstract# 799

45) Rajkumar SV, Jacobus S, Callander N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006; 108: 239a. Abstract# 799

46) Palumbo A, Falco P, Falcone A, et al. Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood. 2006; 108: 240a. Abstract# 800

47) Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002; 99: 3163-8

48) Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004; 73: 98-103

49) Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007; 109: 2604-6

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp